HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Cullinan Oncology (NASDAQ:CGEM) and maintained a $34 price target.
March 14, 2024 | 4:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Cullinan Oncology with a $34 price target.
The reiteration of a Buy rating and maintenance of a $34 price target by a reputable analyst like Edward White suggests a strong bullish sentiment towards Cullinan Oncology. This endorsement could positively influence investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100